Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

STATUS

Recruiting
participants needed

60
sponsor

Yantai Yuhuangding Hospital

Send

Updated on 19 February 2024

See if I qualify

psychiatric disorder

cancer

platelet count

metastasis

solid tumor

brain metastases

advanced solid tumor

advanced malignant solid tumor

Summary

Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

Description

Patients in group A will receive 4 cycles of DC-CIK treatments within 8 months. Patients in group B will have no immunotherapy. Chemotherapy are available in both groups.The investigators want to evaluate the efficacy of combination of DC-CIK with chemotherapy in patients with treatment-refractory solid tumors.

Details

Condition	Solid Tumor
Age	10-90 years
Treatment	DC-CIK combined with Chemotherapy, Chemotherapy
Clinical Study Identifier	NCT04214717
Sponsor	Yantai Yuhuangding Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients with treatment-refractory advanced solid cancer can not accept operation
	Age 18 to 75 years
	Eastern Cooperative Oncology Group (ECOG) score 2 points
	estimate survival > 3 months
	Blood White Blood Cell(WBC) 4109/L, Hb 100g/L, Platelet Count (PLT) 80109/L; Alanine amino transferase (ALT) and aspartate amino transferase (AST) 2 times of normal upper value; Serum Cr 2 normal upper value
	Without any other malignant disease
	With more than one scalable lesions
	Patients Voluntary attempt, and informed consent
	Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus
Exclusion Criteria
	Patients who do not conform to the inclusion criteria
	Patients with uncontrolled infection; underlying disease that was severe or life-threatening (such as uncontrolled brain metastasis )
	Patients who were pregnant or lactating
	ECOG perform status 2;4
	Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

advanced malignant solid tumor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor